386 related articles for article (PubMed ID: 30776691)
1. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
2. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
[TBL] [Abstract][Full Text] [Related]
4. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.
Cotman AE; Trampuž M; Brvar M; Kikelj D; Ilaš J; Peterlin-Mašič L; Montalvão S; Tammela P; Frlan R
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28621824
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
8. New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus.
Samir M; Ramadan M; Abdelrahman MH; Elbastawesy MAI; Halby HM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Med Chem; 2022 Nov; 73():117004. PubMed ID: 36148773
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
10. Action mechanism of 6, 6'-dihydroxythiobinupharidine from Nuphar japonicum, which showed anti-MRSA and anti-VRE activities.
Okamura S; Nishiyama E; Yamazaki T; Otsuka N; Taniguchi S; Ogawa W; Hatano T; Tsuchiya T; Kuroda T
Biochim Biophys Acta; 2015 Jun; 1850(6):1245-52. PubMed ID: 25731981
[TBL] [Abstract][Full Text] [Related]
11. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
[TBL] [Abstract][Full Text] [Related]
12. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel 2-aminobenzothiazole derivatives as potential antimicrobial agents with dual DNA gyrase/topoisomerase IV inhibition.
Ismail MMF; Abdulwahab HG; Nossier ES; El Menofy NG; Abdelkhalek BA
Bioorg Chem; 2020 Jan; 94():103437. PubMed ID: 31812260
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
16. Second-generation 4,5,6,7-tetrahydrobenzo[
Lamut A; Skok Ž; Barančoková M; Gutierrez LJ; Cruz CD; Tammela P; Draskovits G; Szili PÉ; Nyerges Á; Pál C; Molek P; Bratkovič T; Ilaš J; Zidar N; Zega A; Enriz RD; Kikelj D; Tomašič T
Future Med Chem; 2020 Feb; 12(4):277-297. PubMed ID: 32043377
[No Abstract] [Full Text] [Related]
17. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
[TBL] [Abstract][Full Text] [Related]
19. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]